Solid Financial Performance
SWK Holdings reported $8.2 million of net income in the finance segment, with an 8% increase in non-GAAP tangible financing book value per share to $21.15.
Successful Capital Deployment
Deployed $44 million into yielding finance receivables to life science companies, indicating strong operational activity.
Strategic Loan Transactions
Closed multiple significant loans, including an up to $8 million senior secured term loan to Triple Ring Technologies and a $15 million term loan with Impedimed.
Successful Receivable Repayments
Three finance receivables were repaid at premiums, including a 45% IRR from Veru's $4.2 million payment and a 20% IRR from MolecuLight's $12.2 million payment.
MOD3 Pharma Revenue Growth
MOD3 Pharma, formerly Enteris CDMO, tripled its revenue from $1.2 million in 2023 to $3.6 million in 2024, with expectations for continued growth.
Strong Cash Position
SWK Holdings has over $30 million in cash, with no borrowings under its revolver, and expects to increase cash to nearly $70 million following the close of transactions.